35 results on '"Marcucci, Guido"'
Search Results
2. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab
3. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy
4. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
5. Phase 1 Trial Investigating the Safety and Tolerability of Leflunomide in Patients with Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Cell Transplant (alloHCT)
6. Eculizumab Treatment Outcomes in Patients with Allogeneic Hematopoietic Cell Transplant (alloHCT)-Associated Thrombotic Microangiopathy (TA-TMA): A Retrospective Single-Center Experience
7. Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
8. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis
9. Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide
10. Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission
11. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
12. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients
13. Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies
14. Fludarabine and Melphalan (FM) with Post-Transplant Cyclophosphamide (PTCy) for Peripheral Blood Stem Cell (PBSC) Allogeneic Hematopoietic Cell Transplant (HCT) in Patients with Hematologic Malignancies
15. Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients 75 Years and Older: Another Age Barrier Crossed?
16. Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with Measurable Residual Disease and the Impact of Conditioning Regimen and Graft-Versus-Host Disease Prophylaxis Intensity: A Single Center Retrospective Analysis
17. Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia
18. Outcomes of MDS Patients with and without Spliceosome Mutations Undergoing Allogeneic Hematopoietic Cell Transplantation
19. The Effect of Mycophenolate Mofetil Dose per Kilogram on Outcomes of Haploidentical Donor Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide
20. Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors
21. Post-transplant sinusoidal obstruction syndrome in adult patients with B-cell Acute Lymphoblastic Leukemia treated with pre-transplant Inotuzumab
22. Adverse Impact of Renal Impairment on Outcome of Patients Undergoing Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation
23. Favorable Activity of CD19-Targeted Chimeric Antigen Receptor (CD19CAR) T Cell Therapy in Adults with Relapsed/ Refractory (R/R) ALL Including Extramedullary Disease (EMD) and Ph-like Genotype, Using Naive/Memory (Tn/ Mem) Derived T Cells
24. Outcomes of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Adults with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)
25. 569 - Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients 75 Years and Older: Another Age Barrier Crossed?
26. 363 - The Effect of Mycophenolate Mofetil Dose per Kilogram on Outcomes of Haploidentical Donor Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide
27. 219 - Fludarabine and Melphalan (FM) with Post-Transplant Cyclophosphamide (PTCy) for Peripheral Blood Stem Cell (PBSC) Allogeneic Hematopoietic Cell Transplant (HCT) in Patients with Hematologic Malignancies
28. 133 - Myeloablative Vs Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation in Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia
29. 146 - Long Term Outcomes of Patients with Chronic Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation in the Era of Oral Tyrosine Kinase Inhibitors
30. 145 - Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with Measurable Residual Disease and the Impact of Conditioning Regimen and Graft-Versus-Host Disease Prophylaxis Intensity: A Single Center Retrospective Analysis
31. 127 - Outcomes of MDS Patients with and without Spliceosome Mutations Undergoing Allogeneic Hematopoietic Cell Transplantation
32. 316 - Adverse Impact of Renal Impairment on Outcome of Patients Undergoing Melphalan-Based Reduced Intensity Allogeneic Hematopoietic Cell Transplantation
33. 246 - Favorable Activity of CD19-Targeted Chimeric Antigen Receptor (CD19CAR) T Cell Therapy in Adults with Relapsed/ Refractory (R/R) ALL Including Extramedullary Disease (EMD) and Ph-like Genotype, Using Naive/Memory (Tn/ Mem) Derived T Cells
34. 147 - Outcomes of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Adults with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL)
35. Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.